- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
September 7th, 2007
NanoCor Therapeutics has landed a $3.75 million investment from medical device firm Medtronic, The News & Observer reported Friday.
The company is using technology at the University of North Carolina at Chapel Hill to use a genetically engineered virus as a means of drug delivery. Its initial target is people suffering from congestive heart failure. The company calls its technology platform "biological nanoparticle."
|Related News Press|
Forge Nano raises $20 million in Series A Funding: Nano coating technology innovator Forge Nano will use funding to expand manufacturing capacity and grow Lithium-Ion battery opportunities November 3rd, 2016
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016
Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016
UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016
Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016